Table 1. Characteristics of trials included in meta-analyses.

Study	Year	methods	Ethnicity	Cases		Controls		Study design	Control source
				Positive Total		Positive Total
Rogers [14]	2004	IHC	Caucasian	12	17	0	7	cohort	biopsy negative
Shah [15]	2013	IHC	Caucasian	48	51	2.5	3	cohort	benign control
Trpkov [16]	2009	IHC	Caucasian	120	124	16	20	cohort	biopsy negative
Zhou [17]	2004	IHC	Caucasian	176	215	4	11	case series	benign control
Kaic [18]	2009	IHC	Caucasian	9	16	0	4	case series	benign control
Farinola [19]	2004	IHC	Caucasian	16	23	2	16	cohort	benign control
Puebla-Mora[20]	2006	IHC	Caucasian	37	41	6	22	cohort	benign control
Pertega-Gomes [21]	2013	IHC	Caucasian	270	349	12	203	cohort	benign control
Browne [22]	2004	IHC	Caucasian	40	44	2	33	cohort	benign control
Nassar [23]	2005	IHC	Caucasian	34	38	0	15	case series	benign control
Jiang [24]	2005	IHC	Caucasian	78	82	0	56	case series	benign control
Stewart [25]	2007	IHC	Caucasian	272	320	0	292	case series	benign control
Yamada [26]	2013	IHC	Asia	42	60	9	19	cohort	biopsy negative
Chen G [27]	2004	IHC	Asia	71	78	3	68	case series	benign control
Xiao [28]	2004	IHC	Asia	103	105	19	135	case series	benign control
Ng [29]	2007	IHC	Asia	111	113	4	134	case series	benign control
Yu [30]	2007	IHC	Asia	42	42	0	30	case series	benign control
Zielie [31]	2004	RT-PCR	Caucasian	7	10	9	9	case series	benign control
Jiang Z [32]	2004	RT-PCR	Caucasian	441	454	254	277	case series	benign control
Kristiansen [33]	2008	RT-PCR	Caucasian	583	614	0	31	case series	benign control
Schostak [34]	2006	RT-PCR	Caucasian	37	57	8	55	case series	benign control
Ouyang [35]	2008	RT-PCR	Caucasian	30	43	14	49	case series	benign control

IHC = Immunohistochemistry; RT-PCR = Reverse Transcription-Polymerase Chain Reaction.